Global Huntington’s Disease Treatment Market Valuation and Growth Prospects: $1.32 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the huntington’s disease treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Huntington’s Disease Treatment Market Size?

The Huntington’s disease treatment market has experienced significant expansion recently. Its value is projected to rise from $0.73 billion in 2024 to $0.82 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. This historical growth can be attributed to several factors, including heightened awareness of genetic disorders, enhanced accessibility to genetic testing, increasing investment in neurodegenerative disease research, a surge in clinical trials for experimental therapies, and an expanding pipeline of disease-modifying drugs.

The Huntington’s disease treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of “$1.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.6%. This projected increase during the forecast period is driven by several factors, including an intensified focus on personalized medicine, greater adoption of digital health monitoring, increased regulatory backing for orphan drugs, a rising need for therapies offering symptomatic relief, and growing demand for treatments that modify the disease course. Key developments expected during this period encompass technology-driven gene silencing techniques, the advancement of cell-based therapies, the emergence of peripheral biomarkers, the incorporation of telehealth into HD care, the integration of patient-reported outcomes, and ongoing innovation in disease-modifying drugs.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

What Core Market Drivers Are Expanding The Huntington’s Disease Treatment Industry?

The growing application of gene therapies is anticipated to boost the expansion of the Huntington’s disease treatment market in the coming years. Gene therapies are medical interventions designed to modify or replace faulty genes, aiming to cure or prevent illnesses at their fundamental genetic level. As precision medicine progresses, gene therapies are gaining prominence, enabling direct targeting of genetic causes and yielding improved outcomes compared to conventional treatments. In the context of Huntington’s disease, gene therapies function by silencing the defective HTT gene, which is responsible for generating harmful proteins, thus preventing damage to nerve cells. This approach aids in slowing the disease’s progression, preserving brain function, and offers the potential for long-term management. For instance, in July 2023, according to information from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, the number of gene therapies in phase II was 247 at the end of Q1 2023, and this figure subsequently increased by 5% to reach 260 by the end of Q2. Thus, the expansion in gene therapies is a key driver for the growth of the Huntington’s disease treatment market.

What Segment Insights Are Highlighted In The Huntington’s Disease Treatment Market Report?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Notable Trends Are Transforming The Huntington’s Disease Treatment Market Outlook?

Companies operating within the Huntington’s disease treatment market are prioritizing the development of advanced therapies, including selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially improve patient quality of life and slow the disease’s advancement. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein involved in the packaging of neurotransmitters for release within the brain. These drugs contribute to reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for addressing chorea associated with Huntington’s disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor that functions by decreasing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is offered in multiple capsule strengths and can be taken independently of food, providing a convenient dosing choice for patients.

Which Firms Are Driving Innovation Within The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Regional Trends Are Shaping Growth In The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2025, By The Business Research Company

Brain Tumor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795